I just learned that CVS Caremark has decided to put some pharmacogenomics testing in place for a variety of clinical areas, including cancer, cardiovascular disease and HIV. This is an alliance with Generation Health. I am a CVS Caremark customer (thank you, Stanford), and I am thrilled to learn that they are doing this. It raises the possibility that PGx penetration will happen not by FDA decree or government reimbursement agencies, but by pharmacy benefits companies that see real value to them and their customers. It will be very interesting to see how this goes. CVS Caremark is a big company that serves 60 million people. If their competitors follow suit, we may see the benefits of pharmacogenomics reaching patients much sooner than might occur if we wait for other routes to materialize.